Casdin Capital 13F holdings, Q2 2024
Holdings as of June 30, 2024 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 38 US equity positions worth $1.3bn in its Q2 2024 13F filing. The largest position was BLFS at 14.2% of the reported book, followed by RVMD and SRPT. Against the Q1 2024 filing, it opened 4 new positions, added to 7 and reduced 4 among the top 38 holdings.
What did Casdin Capital own in Q2 2024? Top 38 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2024 |
|---|---|---|---|---|---|---|---|
| 1 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 14.2% | $186.6m | 8,707,165 | 0% | held |
| 2 | RVMD REVOLUTION MEDICINES INC | Healthcare | 13.1% | $171.0m | 4,406,875 | -22% | reduced |
| 3 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 13.0% | $169.6m | 1,073,500 | 0% | held |
| 4 | LAB STANDARD BIOTOOLS INC | Healthcare | 8.6% | $113.2m | 63,959,677 | 3% | added |
| 5 | WGS GENEDX HOLDINGS CORP | Healthcare | 7.0% | $92.2m | 3,526,411 | 12% | added |
| 6 | AVIDITY BIOSCIENCES INC | 6.5% | $85.2m | 2,084,841 | 0% | held | |
| 7 | RLAY RELAY THERAPEUTICS INC | Healthcare | 4.2% | $55.1m | 8,448,574 | 14% | added |
| 8 | ILMN ILLUMINA INC | Healthcare | 3.8% | $50.1m | 480,000 | 94% | added |
| 9 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 3.4% | $44.8m | 2,000,000 | 7% | added |
| 10 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 3.2% | $41.3m | 170,000 | -53% | reduced |
| 11 | 2655787D BLUEPRINT MEDICINES CORP | 2.7% | $35.2m | 326,378 | 0% | held | |
| 12 | DNLI DENALI THERAPEUTICS INC | Healthcare | 2.3% | $30.2m | 1,300,000 | 0% | held |
| 13 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 2.1% | $27.5m | 700,000 | -37% | reduced |
| 14 | EXK EXACT SCIENCES CORP | Basic Materials | 2.1% | $27.5m | 650,000 | 0% | held |
| 15 | TNYA TENAYA THERAPEUTICS INC | 1.6% | $20.9m | 6,732,971 | 0% | held | |
| 16 | NGNE NEUROGENE INC | 1.5% | $19.1m | 524,616 | 0% | held | |
| 17 | VCYT VERACYTE INC | Healthcare | 1.4% | $18.6m | 857,904 | 0% | held |
| 18 | 4D MOLECULAR THERAPEUTICS IN | 1.3% | $16.8m | 800,000 | 0% | held | |
| 19 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.2% | $15.8m | 675,000 | 0% | held |
| 20 | VERVE THERAPEUTICS INC | 1.1% | $14.9m | 3,059,094 | 0% | held | |
| 21 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 1.0% | $13.2m | 5,190,506 | 62% | added |
| 22 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 0.8% | $10.8m | 1,000,000 | 0% | held |
| 23 | TNGX TANGO THERAPEUTICS INC | Healthcare | 0.8% | $10.2m | 1,188,349 | 0% | held |
| 24 | 2SEVENTY BIO INC | 0.6% | $7.7m | 2,000,000 | 0% | held | |
| 25 | CDXS CODEXIS INC | Healthcare | 0.5% | $6.2m | 2,000,000 | 0% | held |
| 26 | CTNM CONTINEUM THERAPEUTICS INC | 0.4% | $5.2m | 296,666 | – | new | |
| 27 | KYTX KYVERNA THERAPEUTICS INC | 0.3% | $4.3m | 575,000 | 283% | added | |
| 28 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.2% | $3.1m | 150,000 | 0% | held |
| 29 | ABSI ABSCI CORPORATION | 0.2% | $3.0m | 973,260 | 0% | held | |
| 30 | GH GUARDANT HEALTH INC | Healthcare | 0.2% | $2.9m | 100,000 | – | new |
| 31 | PRME PRIME MEDICINE INC | 0.1% | $1.9m | 367,175 | 0% | held | |
| 32 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 0.1% | $1.4m | 1,035,859 | 0% | held |
| 33 | GRAL GRAIL INC | 0.1% | $1.2m | 79,999 | – | new | |
| 34 | EXSCIENTIA PLC | 0.1% | $1.1m | 213,900 | 0% | held | |
| 35 | GLUE MONTE ROSA THERAPEUTICS INC | 0.1% | $976.2k | 261,014 | -49% | reduced | |
| 36 | GINKGO BIOWORKS HOLDINGS INC | 0.0% | $488.0k | 1,459,747 | 0% | held | |
| 37 | SINGULAR GENOMICS SYSTEMS IN | 0.0% | $372.9k | 44,129 | – | new | |
| 38 | KRONOS BIO INC | 0.0% | $153.6k | 123,839 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.